[Gemcitabine in advanced stage soft tissue sarcoma: a phase II study].
OBJECTIVE
To assess the activity and toxicity of gemcitabine in locally advanced or metastatic soft tissue sarcoma patients (pts).


METHODS
Gemcitabine was administered on days 1, 8, 15 every 4 weeks at a dose of 1.000/1.250 mg/m2, respectively, in pretreated or not pretreated pts.


RESULTS
Eighteen pts entered this phase II trial; sixteen had been previously treated with anthracyclines and ifosfamide. A partial response was observed in a woman with fibrous malignant istocytoma, whereas in 7 pts the disease remained stable. Median time to progression was 4 months. The treatment was well tolerated. Grade 4 toxicity was not observed.


CONCLUSIONS
These results do not suggest that gemcitabine, in the dose and schedule used in this trial, may be of value in the treatment of soft tissue sarcomas.
Amodio
A
A
Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
Carpano
S
S
Manfredi
C
C
Del Monte
G
G
Di Lauro
L
L
Gionfra
T
T
Conti
F
F
Paoletti
G
G
Lopez
M
M
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D012509:Sarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
Gemcitabina nei sarcomi dei tessuti molli in fase avanzata: studio di fase II.